The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
 
Darren Cowzer
No Relationships to Disclose
 
Risha Huq
No Relationships to Disclose
 
Maria Perry
No Relationships to Disclose
 
Fergus Keane
No Relationships to Disclose
 
Wungki Park
Consulting or Advisory Role - Aegle; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Imane H. El Dika
Honoraria - Lynx Group
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Danny Khalil
Consulting or Advisory Role - Abbvie; PsiOxus Therapeutics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination.
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Carlie S. Sigel
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Lilly; PetDx
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Fog Therapeutics; Fore Biotherapeutics; Pfizer; Scorpion Therapeutics; Vividion Therapeutics
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)